Your browser doesn't support javascript.
loading
Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma.
Rozeman, E A; Hoefsmit, E P; Reijers, I L M; Saw, R P M; Versluis, J M; Krijgsman, O; Dimitriadis, P; Sikorska, K; van de Wiel, B A; Eriksson, H; Gonzalez, M; Torres Acosta, A; Grijpink-Ongering, L G; Shannon, K; Haanen, J B A G; Stretch, J; Ch'ng, S; Nieweg, O E; Mallo, H A; Adriaansz, S; Kerkhoven, R M; Cornelissen, S; Broeks, A; Klop, W M C; Zuur, C L; van Houdt, W J; Peeper, D S; Spillane, A J; van Akkooi, A C J; Scolyer, R A; Schumacher, T N M; Menzies, A M; Long, G V; Blank, C U.
Afiliação
  • Rozeman EA; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Hoefsmit EP; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Reijers ILM; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Saw RPM; Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.
  • Versluis JM; Department of Surgery, Mater Hospital, Sydney, New South Wales, Australia.
  • Krijgsman O; Department of Surgery, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.
  • Dimitriadis P; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Sikorska K; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • van de Wiel BA; Oncode Institute, Utrecht, the Netherlands.
  • Eriksson H; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Gonzalez M; Department of Biometrics, Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Torres Acosta A; Department of Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Grijpink-Ongering LG; Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden.
  • Shannon K; Department of Oncology/Skin Cancer Center, Theme Cancer, Karolinska University Hospital, Stockholm, Sweden.
  • Haanen JBAG; Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.
  • Stretch J; Department of Biometrics, Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Ch'ng S; Department of Biometrics, Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Nieweg OE; Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.
  • Mallo HA; Department of Surgery, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.
  • Adriaansz S; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Kerkhoven RM; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Cornelissen S; Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.
  • Broeks A; Department of Surgery, Mater Hospital, Sydney, New South Wales, Australia.
  • Klop WMC; Department of Surgery, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.
  • Zuur CL; Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.
  • van Houdt WJ; Department of Surgery, Mater Hospital, Sydney, New South Wales, Australia.
  • Peeper DS; Department of Surgery, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.
  • Spillane AJ; Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.
  • van Akkooi ACJ; Department of Surgery, Mater Hospital, Sydney, New South Wales, Australia.
  • Scolyer RA; Department of Surgery, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.
  • Schumacher TNM; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Menzies AM; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Long GV; Genomics Core Facility, Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Blank CU; Core Facility Molecular Pathology and Biobanking, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Nat Med ; 27(2): 256-263, 2021 02.
Article em En | MEDLINE | ID: mdl-33558721
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Ipilimumab / Nivolumabe / Melanoma Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Nat Med Assunto da revista: BIOLOGIA MOLECULAR / MEDICINA Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Holanda
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Ipilimumab / Nivolumabe / Melanoma Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Nat Med Assunto da revista: BIOLOGIA MOLECULAR / MEDICINA Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Holanda